Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy

1980 ◽  
Vol 45 (6) ◽  
pp. 1258-1264 ◽  
Author(s):  
Peter Hanrath ◽  
Detlef G. Mathey ◽  
Peter Kremer ◽  
Frank Sonntag ◽  
Walter Bleifeld
2017 ◽  
Vol 41 (3) ◽  
pp. 339-343
Author(s):  
Itai Ghersin ◽  
Eduard Ghersin ◽  
Sobhi Abadi ◽  
Jennifer E. Runco Therrien ◽  
Tanyanan Tanawuttiwat ◽  
...  

2004 ◽  
Vol 17 (4) ◽  
pp. 330-331 ◽  
Author(s):  
Antonio De Merulis ◽  
Giulio Calcagni ◽  
Paolo Versacci ◽  
Renato Lucchini ◽  
Flavia Ventriglia ◽  
...  

Circulation ◽  
1999 ◽  
Vol 99 (2) ◽  
pp. 254-261 ◽  
Author(s):  
Sherif F. Nagueh ◽  
Nasser M. Lakkis ◽  
Katherine J. Middleton ◽  
William H. Spencer ◽  
William A. Zoghbi ◽  
...  

1999 ◽  
Vol 35 (4) ◽  
pp. 285-291 ◽  
Author(s):  
JM Bright ◽  
ME Herrtage ◽  
JF Schneider

Left ventricular (LV) diastolic function was evaluated in 16 cats with primary hypertrophic cardiomyopathy (HCM) using pulsed Doppler (PD) assessment of transmitral flow and isovolumic relaxation time. Data obtained was compared to data from 12 healthy, adult, research cats. Compared to normal cats, the HCM group showed significantly (p value less than 0.05) reduced early LV inflow velocities (mean +/- standard error [SE], peak velocity of 0.70+/-0.04 m/s versus 0.54+/-0.04 m/s and integrated velocity of 0.48+/-0.08 m/s versus 0.37+/-0.03 m/s); a reduced rate of deceleration of early inflow (mean+/-SE, -12.0+/-1.0 m/s2 versus -5.1+/-1.1 m/s2); prolonged isovolumic relaxation time (mean +/- SE, 45.7+/-3.3 ms versus 76.0+/-3.1 ms); and increased atrial systolic flow velocities (mean +/- SE, peak velocity of 0.29+/-0.04 m/s versus 0.48+/-0.04 m/s and integrated velocity of 0.21+/-0.03 m/s versus 0.34+/-0.03 m/s). The results suggest that PD provides a noninvasive method of identifying and quantifying functional diastolic impairment in cats with HCM.


1995 ◽  
Vol 88 (2) ◽  
pp. 159-164 ◽  
Author(s):  
Peter B. M. Clarkson ◽  
Nigel M. Wheeldon ◽  
Catherine MacLeod ◽  
Wendy Coutie ◽  
Thomas M. MacDonald

1. Elevated plasma concentrations of brain natriuretic peptide are found in conditions associated with impaired left ventricular diastolic function. The purpose of this study was to determine whether this peptide actually plays a physiological role in improving myocardial performance in diastole. 2. Nine normal subjects received infusions of brain natriuretic peptide or placebo in a randomized, double-blind, crossover study. Brain natriuretic peptide infusion produced a significant reduction in isovolumic relaxation time (means and 95% confidence interval for difference−10.8 ms, −14.5 to −7.0 ms) (P < 0.01) and significantly increased both the peak E/A velocity (0.54, 0.14–0.94) (P < 0.05) and the E/A time velocity integral (1.09, 0.20–1.98) (P < 0.05). 3. These responses were evident at concentrations of brain natriuretic peptide that produced no associated effects on blood pressure, heart rate or stroke distance. 4. Brain natriuretic peptide infusion in normal subjects significantly reduces isovolumic relaxation time and improves transmitral Doppler flow profiles, suggesting that this peptide may be important in the control of left ventricular diastolic relaxation in man.


Sign in / Sign up

Export Citation Format

Share Document